News
We send the latest information from SMC Laboratories.
What is the relationship between NASH and Liver Cancer?
You may know that liver cancer is one of the most prevalent cancers, but do you know about its relationship wi…
SMC attend BIO Partnering at JPM Week!
We are pleased to announce that SMC Laboratories will be virtually attending the BIO One-on-One Partnering eve…
Long-COVID, COVID-19 variants, and the emergence of pulmonary fibrosis in recovered COVID-19 patients
COVID-19 is a virus belonging to the beta-coronavirus class, similar to the virus that causes severe acute res…
Marvel Biosciences has published a press release regarding the MB-207 efficacy evaluation study for liver fibrosis provided by SMC
Marvel Biosciences, which is our client, has announced the results of pharmacology study using a STAM™ m…
SMC announces Presentation of New Data at the KDDW 2021
We are pleased to announce the acceptance of our abstracts, “Molecular Pathogenesis of Non-Alcoholi…
STZ: Type 1 or Type 2 Diabetes?
When discussing our unique NASH-HCC model STAM with clients, we are so often asked: What type of diabetes does…
Reserve a non-clinical pharmacology consultation with us at BioPharm America!
We are joining BioPharm America™ Digital, one of the most famous virtual biotech partnering and educatio…
BioJapan – join us!
We will be attending the annual 24th BioJapan from Wednesday, October 13th, 2021 – Friday, October 15th,…
Lung fibrosis in COVID-19
COVID-19 is now being recognized as a multi-organ disease that causes not only pneumonia, but also cause damag…
ENYO Pharma announces positive Vonafexor (EYP001) results for the LIVIFY phase 2a study in F2-F3 NASH patients over 12 weeks
ENYO Pharma (France) announced on 28 July, 2021, positive Vonafexor (EYP001) results for the LIVIFY phase 2a s…